ABVC BioPharma Provides Vitargus® Update
June 30, 2022 08:30 ET
|
ABVC BioPharma, Inc.
Vitargus® Receives Phase II Thailand Central Research Ethics Committee Approval FREMONT, CA, June 30, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC), a...
ABVC BioPharma Submitted Vitargus® Phase II Study Plan to Australia HREC
June 16, 2022 08:30 ET
|
ABVC BioPharma, Inc.
FREMONT, CA, June 16, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC Biopharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in...
ABVC BioPharma Announces Enrollment Progress for ADHD Phase II Part 2 Clinical Study
June 01, 2022 08:30 ET
|
ABVC BioPharma, Inc.
FREMONT, CA, June 01, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC Biopharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in...
ABVC BioPharma Enters Into $3.0 Million Clinical Services Contract with NeuCen BioMed
May 03, 2022 08:30 ET
|
ABVC BioPharma, Inc.
FREMONT, CA, May 03, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC Biopharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in...
ABVC BioPharma Restructures Joint Venture to Expand Access to Early-Stage Research
October 12, 2021 08:30 ET
|
ABVC BioPharma, Inc.
Restructured Venture Also Seeks Licensing Partners for ABVC FREMONT, CA, Oct. 12, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC Biopharma, Inc. (NASDAQ: ABVC), a clinical-stage biopharmaceutical...
ABVC BioPharma Report Updated by Zacks/SCR
August 30, 2021 08:30 ET
|
ABVC BioPharma, Inc.
FREMONT, CA, Aug. 30, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in...